Menu

Experience

Phil Mitchell

    • Forbius Agrees to Sell to Bristol Myers Squibb 


    • Thrive Capital Invests in Oscar's $225 Million Financing Round 


    • ArcherDX Agrees to Combine With Invitae in $1.4 Billion Deal 


    • Avidity Biosciences - $289 Million IPO 


    • Vaxcyte - $288 Milion IPO 


    • Reata Pharmaceuticals – $505 Million Follow-On Offering 


    • argenx – $557 Million Follow-On Offering 


    • Innate Pharma - $79 Million IPO 


    • Vir Biotechnology - $143 Million IPO 


    • ERYTECH – $144 Million IPO 


    • Cooley Advises on Nightstar + NuCana IPOs 


    • Aridis – $26 Million IPO 


    • Advaxis – $30 Million Registered Direct Offering 


    • Recro Pharma – $15 Million Follow-On  


    • Gemphire Therapeutics – $30 Million IPO 


    • Syros – $58 Million IPO 


    • Syros IPO – $58 Million 


    • Selecta Biosciences – $74 Million IPO 


    • Oncobiologics – $40 Million IPO and Private Placement 


    • Inotek Pharmaceuticals – $50 Million Follow-On 


    • Auxogyn and Fertility Authority Announce Merger 


    • AveXis – $95 Million IPO 


    • WAVE Life Sciences - $102 Million IPO 


    • Voyager Therapeutics - $80.5 Million IPO 


    • Strongbridge Biopharma IPO 


    • Aclaris Therapeutics IPO 


    • NantKwest IPO - $238 Million IPO 


    • ProNAi Therapeutics - $158 Million IPO 


    • Chiasma Completes $117 Million IPO 


    • Celyad Completes IPO 


    • NantKwest – $238 Million IPO 


    • Catabasis Completes $69 Million IPO 


    • ProNAi – $158 Million IPO 


    • MINDBODY Completes $100 Million IPO 


    • MINDBODY Completes $100 Million IPO 


    • HTG Completes its Initial Public Offering 


    • Aduro Completes $137 Million IPO 


    • KemPharm Completes its IPO 


    • Cidara Completes Initial Public Offering  


    • Invitae Completes $117 Million Initial Public Offering  


    • Ascendis Pharma closes $124 million IPO 


    • Bellicum Pharmaceuticals $160 million IPO 


    • TRACON Pharmaceuticals Completes Initial Public Offering 


    • DBV Technologies Completes Concurrent Public Offerings 


    • Sientra Completes $75 Million Initial Public Offering 


    • Demira Prices $125 Million IPO 


    • T2 Biosystems IPO 


    • Vitae Pharmaceuticals Completes Initial Public Offering  


    • Otonomy $100 Million IPO 


    • Immune Design $63 Million Initial Public Offering 


    • HealthEquity $146 Million Initial Public Offering 


    • Intersect ENT Initial Public Offering 


    • Minerva Neurosciences $32.7 Million IPO 


    • Kite Pharma $146 Million Initial Public Offering 


    • TriVascular Initial Public Offering 


    • Vital Therapies Initial Public Offering 


    • Cooley Advises Underwriters on Vital Therapies IPO 


    • Amedica Initial Public Offering 


    • Genocea Biosciences IPO 


    • Apollo Endosurgery Agreement Acquire Obesity Intervention Division of Allergan 


    • Minerva – $58 Million Follow-On Offering 


    • Merus IPO – $61 Million 


Contact us

Back to top

© 2020 Cooley LLP and Cooley (UK) LLP. All rights reserved.

Cooley® is a registered service mark of Cooley LLP in the United States and European Union as well as certain other jurisdictions.